CAP TODAY Pathology/Laboratory Medicine/Laboratory Management
GeneDx announced the launch of a comprehensive suite of genetic tests for inherited cancer, including a 26-gene panel for breast and ovarian cancer that includes BRCA1 and BRCA2 and next-generation sequencing-based multi-gene panels for colorectal cancer, pancreatic cancer, and endometrial cancer.
Test offerings include a rapid turnaround test of the BRCA1 and BRCA2 genes combining sequencing and deletion/duplication analysis; an Ashkenazi Jewish panel for the three common Ashkenazi Jewish founder mutations in BRCA1 and BRCA2; a 26-gene panel for breast and ovarian cancer; an 18-gene panel for pancreatic cancer; an 18-gene panel for colorectal cancer; and an 11-gene panel for endometrial cancer. The test panels, which are marketed as OncoGeneDx, also include a comprehensive cancer panel of 35 genes. All panels include deletion/duplication assessment.
Although BRCA1/2 gene sequencing has been available for years, comprehensive evaluation for deletions and duplications in those genes was launched only recently and has not been available to many patients due to payer restrictions. OncoGeneDx panels include deletion/duplication analysis of genes in each panel at no additional charge.
GeneDx, 301-519-2100